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Background
Rheumatological disorders such as rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE) and spondyloarthropathies 
(SpAs) (including psoriatic arthritis (PsA) and ankylosing spondylitis 
(AS)) place a considerable disease burden upon individuals and 
upon society in general. The severity and chronicity of these diseases 
have far-reaching implications for the economy, and for patients 
themselves because of loss of capacity to work due to irreversible joint 
damage, reduced life expectancy, and acceleration of other disease 
processes including cardiovascular disease and lymphoma.[1-4]
Current therapy
The mainstay of treatment for these conditions includes a variety 
of immunosuppressive medications, aiming to control the 
inflammatory processes that drive progressive damage of various 
systems, including the musculoskeletal and other organ systems. 
For RA, early initiation of conventional synthetic disease-modifying 
antirheumatic drugs (csDMARDs), of which methotrexate (MTX) 
remains the cornerstone, is essential. However, the majority (66%) 
of patients with RA will fail to achieve full disease remission on 
MTX monotherapy, an alternative csDMARD (87%) or csDMARD 
combination therapy (64%).[5,6] Hodkinson et al.[7] showed that in 
indigent South Africans, fewer than one-third of patients with early 
RA had low disease activity at 12 months.[7] Also, the therapeutic 
options available for conditions such as AS are limited compared 
with other rheumatic diseases, with no oral csDMARDs shown to 
have disease-modifying effects, on axial involvement in particular. [8,9] 
In view of these limitations, there was a clear need for alternative 
therapeutic options in rheumatology.
Biological therapy
Biological disease-modifying antirheumatic drugs (bDMARDs) 
have ultimately become the gold standard of treatment for refractory 
rheumatic conditions in well-resourced countries for patients who 
fail csDMARDs. The bDMARDs are genetically engineered drugs 
manufactured or synthesised in vitro from molecules such as proteins, 
genes and antibodies present in living organisms. These agents 
are then used to target specific components of the inflammatory 
cascade and thereby alter the body’s response to inflammation. [10] 
Most widely used of these biological agents are the class of the 
tumour necrosis factor inhibitors (TNFi). The TNFi have provided 
remarkable improvement for patients with refractory RA, but a 
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Conclusions. Recurrent uveitis occurred in almost half of the patients with AS and was also the main reason for discontinuation of 
biological therapy. We did not document an increased risk of PTB. Disease activity scores showed significant improvement. The study is 
limited by the small number of patients on biological therapy, a reflection of the impact of severe resource constraints.
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prospective study done in South Africa (SA) by Pettipher et al.[11] 
reported that fewer than one-third of patients remained on TNFi, 
mainly owing to infections and inadequate response to treatment, 
thereby highlighting the need for alternative bDMARDs.[11]
The cost of these therapies varies depending on the specific 
rheumatological condition, the dose required and the weight of 
the patient. Estimated costs in the public sector range between 
ZAR50  000 per annum for etanercept (Enbrel) to ZAR120 000 per 
annum for adalimumab (Humira)[12] – a significant expense compared 
with MTX, which costs ZAR2 - 3 per 2.5 mg tablet (annual cost at 
maximum dose ZAR1 560), or sulphasalazine, which costs ZAR4 - 6 
per 500 mg tablet (annual cost at maximun dose ZAR1  872). [13] 
To interpret the cost-utility measures of costly therapies in terms 
of their societal acceptance, they are often compared with other 
expensive but widely accepted (and reimbursed) therapies. Cost-
utility ratios of TNFi in RA models based on original progression 
data range from ~EUR3 000 to EUR48 000 per quality-adjusted 
life-year (QALY), and in AS models from EUR15 000 to EUR50 000 
per QALY. These results are within the range of other accepted or 
mandated interventions such as intensive glycaemic control for 
diabetes mellitus, antiretroviral therapy in HIV, haemodialysis, or 
colon cancer screening.[14,15] Most studies evaluating QALYs are done 
in the setting of high-income countries. In low- and middle-income 
countries, the value of labour is low and the majority of workers are 
manual labourers. In this setting, bDMARD therapy aims to protect 
against job losses and may provide unconvincing cost-effective 
returns. However, gains in quality of life for the patient, and their 
family and community, may be considerable.[12]
Biological treatment use in a resource-limited setting
Tygerberg Academic Hospital (TBH) in Cape Town, SA, renders a 
tertiary service to a population of ~3.6 million people. Rheumatology 
is a predominant outpatient-based service, with 4 500 patient 
visits annually. This number includes 1 200 patients with RA and 
200 patients with an SpA, including AS and PsA.
The South African Rheumatism and Arthritis Association 
(SARAA) and the European League Against Rheumatism (EULAR) 
provide guidelines for the use of csDMARDs and bDMARDs based 
on disease activity criteria and failure of first-line oral therapy 
(determined by the underlying disease treated).[9,16-19]
Currently, the SA essential medicines list does not include 
bDMARDs for rheumatological use, while the tertiary and quaternary 
provincial code list (as of 2019) includes rituximab for refractory 
RA.[13] At TBH there are numerous patients who meet the SARAA 
criteria for bDMARDs, but owing to severe resource constraints the 
use of biological therapy is reserved for those who have the worst 
refractory disease.
A combined multidisciplinary decision is then made based on 
accumulated information (disease activity and therapy, socioeconomic 
factors and employment status) to select the most suitable patients for 
biological therapy.
Although SARAA guidelines are followed, access to bDMARDs 
in SA in the public sector is dependent on criteria individually 
developed by various provinces as well as other factors including 
access to and type of medical insurance.
Risk of biological therapy
Tumour necrosis factor (TNF) plays an essential role in the 
inflammatory cascade, which has a protective function against 
infections. Inhibition of TNF has been associated with the reactivation 
of latent infections, specifically tuberculosis (TB). The risk of TB 
reactivation ranges from 5- to 56-fold in varying reports.[20-22] Certain 
TNFi (monoclonal antibodies) appear to have higher associations 
with TB reactivation than other biological therapies such as the 
soluble TNF receptor (etanercept), while the class of anti-CD20 
antibodies (rituximab) appears to have the safest profile.[23]
SA is a TB-endemic country, among the top 8 countries in 
the world with regard to new TB cases in 2019. According to the 
World Health Organization (WHO) global report, 60 million lives 
were saved through effective diagnosis and treatment from 2000 
to 2019, and globally the incidence of TB is falling by 2% per year. 
Ending the TB epidemic by 2030 is one of the health targets of the 
WHO Sustainable Development Goals.[24] The role of bDMARDs 
in resource-limited settings such as SA is still unknown: ‘There is 
a clear need for biologic registries in developing countries to better 
understand their safety and role in a resource limited environment.’[25]
Objectives
The primary objective of the study was to describe the nature and 
frequency of adverse events related to the use of biological treatment, 
as well as the main reason for discontinuation of treatment. Secondary 
objectives included assessing the efficacy of current TB prophylaxis 
protocols, and of the selection criteria for biological therapy with 
regard to retaining or regaining employment.
Methods
We conducted a retrospective, descriptive folder review. All patients 
started on biological therapy at TBH for rheumatic conditions 
from November 2011 (when bDMARDs were first accessed by the 
rheumatology department) to December 2016 were considered for 
inclusion.
Inclusion criteria. All adult patients treated with bDMARDs for 
rheumatic disorders.
Exclusion criteria. Patients treated with bDMARDs for indications 
other than rheumatic disorders.
Patient records were retrieved and manually assessed by the first 
author (JWR). The specific data required were recorded and entered 
into Excel spreadsheet, version 2007 (Microsoft, USA), for evaluation.
Adverse events were defined as ‘undesired harmful effects resulting 
from medication’, and serious adverse events were defined as ‘any 
untoward medical occurrence that at any dose: results in death, is 
life threatening, requires inpatient hospitalisation or prolongation of 
existing hospitalisation, results in persistent or significant disability, 
or requires permanent discontinuation of therapy’.
Statistical analysis
Collected data were sent to the Stellenbosch University biostatistics 
department for basic statistical analysis. Adverse events, both major 
and minor, were calculated as absolute events during the study 
period, stratified according to biological therapy, and displayed as 
frequency plots.
Box-and-whisker plots were used to display improvement in the 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and 
Clinical Disease Activity Index (CDAI) scores in the AS and RA 
groups, respectively. Even though the sample size was small, the 
improvements in BASDAI and CDAI scores were parametrically 
distributed, so the t-test was used to determine statistical significance 
(p-values <0.05 were considered significant).
Ethical considerations
The study was approved by the Health Research Ethics Committee 
of Stellenbosch University (ref. no. S16/10/191). Research was 
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conducted according to the ethical guidelines and principles of the 
International Declaration of Helsinki, the South African Guidelines 
for Good Clinical Practice and the South African Medical Research 
Council ethical guidelines.
All data collected were treated as confidential, and the privacy 
of the subjects was protected. Data for analysis, including any 
publications, will remain anonymous.
Results
A total of 31 patients were included in the study period. Apart from 
discontinuation due to death (1 patient), biological therapy was 
discontinued in 2 patients (7%). None were lost to follow-up.
The spectrum of rheumatological diseases included AS (n=11), RA 
(n=6), PsA (n=2), vasculitides (n=3) and juvenile idiopathic arthritis 
(JIA) (n=4). Biological therapy was also used in 5 refractory cases 
of SLE: lupus myocarditis (n=3), neurolupus (n=1) and idiopathic 
thrombocytopenic purpura (n=1).
Indications for biological use in the vasculitides were Takayasu’s 
arteritis, granulomatosis with polyangiitis (GPA) and severe 
rheumatoid vasculitis.
Non-TNF biologicals included rituximab (SLE and vasculitis, n=7) 
and abatacept (JIA, n=2). Etanercept was used preferentially in 15 
out of 19 patients with RA/SpA because of its cost-effectiveness and 
relative safety profile with regard to acquiring TB, compared with 
monoclonal TNFi.
Adverse events
Adverse events occurred in 26 patients (84%), with some patients 
experiencing more than one adverse event (Figs 1 and 2).
Non-serious adverse events
Seventeen non-serious adverse events occurred in 12 patients 
(39%) (Fig. 1). Skin manifestations (including sebaceous cyst, 
pityriasis versicolor, eczema, chickenpox and folliculitis) and upper 
respiratory tract infections were the most frequent non-serious 
adverse events.
Serious adverse events
Seventeen serious adverse events occurred in 14 patients (45%) 
(Fig. 2). Recurrent uveitis (≥2 episodes) was the most common 
serious adverse event, occurring in 5 patients (16%). This occurred 
exclusively among patients treated for AS (5/11 patients; 45%) 
(Table 1). In 4 patients recurrent uveitis occurred on etanercept, with 
a median (interquartile range) duration of 35 (28 - 40) months before 
the first episode of uveitis. In our study, the incidence rate of uveitis 
events was 27.3 per 100 person-years.
Two patients developed a lupus-like syndrome on infliximab. One 
of them developed a photosensitive rash, with antinuclear antibody 
titres of 1:1 280 and anti-double-strand DNA >200 IU/mL. No other 
features of SLE were present, and the patient did not meet the clinical 
criteria for SLE. The second patient developed an autoimmune 
pericarditis after infliximab treatment.
Two patients developed septic arthritis. The first developed right 
prosthetic hip septic arthritis while on adalimumab. The second was 
an SLE patient who received rituximab for resistant myocarditis and 
neurolupus in October 2014. She also had lupus nephritis (class IV) 
and haemolytic anaemia. She developed Streptococcus pneumoniae 
septic arthritis in 2016 in her left hip, which was damaged as a result 
of avascular necrosis secondary to chronic steroid use.
One patient developed sputum-positive, rifampicin-sensitive 
pulmonary tuberculosis (PTB). He was subsequently switched to 
rituximab (for seropositive RA) after completion of TB treatment, 
with sustained low disease activity. He had no household TB contact, 
and risk factors were those of RA and recently started etanercept. 
This patient did not have evidence of latent tuberculous bacterial 
infection (LTBI) (purified protein derivative <5 mm and a normal 
chest radiograph) when starting etanercept. Although he received 
isoniazid (INH) prophylaxis, this was unfortunately interrupted 
4  months prior to his being diagnosed with sputum-positive PTB. 
He had completed 8 months of etanercept treatment by the time the 
PTB was diagnosed.
One patient died during the study. He was suffering from 
refractory GPA and died despite a second course of rituximab. The 
cause of death was a severe flare of GPA after the patient had been 





























































Fig. 1. Frequency of non-serious adverse events. (URTI = upper respiratory 



































































































Fig. 2. Frequency of serious adverse events.
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in remission following rituximab treatment 5 years previously. The 
rituximab was used as rescue therapy for resistant disease and is 
unlikely to have contributed to his death.
The patient who suffered severe bronchospasm during a rituximab 
infusion for RA was a known asthmatic and was subsequently placed 
on nebulisation.
The patient who developed carcinoid syndrome secondary to a 
neuroendocrine tumour developed symptoms after etanercept was 
started. As far as we are aware, there are no known associations 
between etanercept and neuroendocrine tumours.
Response to treatment
For the AS and RA groups, the median BASDAI and CDAI scores, 
respectively, are reflected in Figs 3 - 6.
For AS, a clinically significant response is defined as ‘improvement 
of at least 50% or 2 units (on a 0 - 10 scale) of the BASDAI’ after 6 - 
12 weeks of treatment.[26] This was achieved in 8 out of 11 patients.
For RA, lack of efficacy was defined as a failure to achieve 
improvement in a CDAI score of 10 - 20 after 3 months or failure 
to achieve a low disease activity CDAI score <10 during the later 
course of treatment. This was achieved in 3 out of 6 patients. (CDAI 
scores were used instead of SDAI scores and based on SARAA 
recommendations.[27])
The SLE patients treated with rituximab for off-label indications 
such as resistant autoimmune myocarditis, resistant neurolupus 
and refractory ITP had varied responses. Two out of 3 patients with 
myocarditis had clinical and echocardiographic improvement, while 
the third patient’s condition remained unchanged. One patient was 
treated for neuropsychiatric symptoms that resolved after treatment. 
One RA patient was treated for vasculitis that responded well to 
rituximab with complete resolution of skin lesions.
A single patient with resistant Takayasu’s arteritis was treated with 
infliximab with improvement in disease activity clinically and as 
evident by positron emission tomography/computed tomography 
follow-up.
Discontinuation or switching to alternative  
biological therapy
Discontinuation or switching of biological therapy occurred in 13/31 
patients (42%). The main reason for discontinuation or switching 
was serious adverse events. Treatment failure occurred in a total of 6 
out of 13 patients (46%), 3 patients each from the RA and AS groups. 
Only 1 patient had treatment failure related to a second biological 
agent by the time the study period ended.
Chemoprophylaxis and vaccinations
None of the patients who received continuous TB prophylaxis or 
treatment for LTBI developed TB disease. A single patient developed 
PTB after discontinuation of INH prophylaxis. Patients on rituximab 
and abatacept did not require chemoprophylaxis.
Employment
Most patients remained employed or continued their schooling 
during our study period, with 1 patient dying and 2 patients gaining 
employment. Two patients reached pensionable age and were no 
longer eligible for employment; 1 had previously been employed.
Discussion
A total of only 31 patients received biological therapy for a variety 
of rheumatological conditions. This includes 23 out of >1 500 
Table 1. Adverse events – recurrent uveitis
Patient
History of previous 










biological until 1st 
episode of uveitis
Switched to second 
biological agent
1 None Recurrent uveitis 
(4 episodes)
Ankylosing spondylitis Etanercept 31 months Infliximab
2 Recurrent uveitis Recurrent uveitis 
(2 episodes)
Ankylosing spondylitis Golimumab 20 months No switch
3 Recurrent uveitis Recurrent uveitis 
(4 episodes)
Ankylosing spondylitis Etanercept 43 months Golimumab
4 None Recurrent uveitis 
(2 episodes)
Ankylosing spondylitis Etanercept 18 months Golimumab
5 Recurrent uveitis Recurrent uveitis 
(3 episodes)
Ankylosing spondylitis Etanercept 39 months Golimumab



















Fig. 3. Response to first biological in ankylosing spndylitis patients (n=11). 
Median (IQR) BASDAI score improved from 6.4 (5 - 7.4) to 2.8 (0.9 - 5.0) 
by the end of the study or discontinuation of the drug (statistically significant 
difference of –3.5 (p<0.001) (95% CI –5.3 - –1.7) over a median (IQR) time 
period of 20 (9 - 30) months). (IQR = interquartile range; BASDAI = Bath 
Ankylosing Spondylitis Disease Activity Index; CI = confidence interval.)
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patients with inflammatory arthritis seen at the outpatient clinic, 
reflecting the current resource constraints and limited access to 
biological agents rather than clinical indications for bDMARDs. 
At the time of the study, access to bDMARDs for RA, SpA and 
PsA was limited to 15 patients according to provincial guidelines. 
Additional patients gained access through individual motivations to 
the hospital pharmaceutical and therapeutics committee. AS was the 
most common condition for which biological therapy was prescribed. 
This probably reflects a selection bias. With a limited total number 
of patients who can gain access to biological therapy, and the limited 
therapeutic options available for AS, these patients were selected 
preferentially above those with conditions such as RA, for which a 
wider range of non-biological csDMARD therapies is available.
Recurrent uveitis was the main serious adverse event in our study, 
occurring in 5/11 (45%) of the AS group, an incidence of 27.3 uveitis 
cases per 100 person-years. This finding is in keeping with the 
increased incidence in the literature.[28-30] In our cohort, uveitis did 
not occur with any of the other conditions. Of the 5 patients who 
developed uveitis, 4 were using etanercept.
Uveitis is the most common extra-articular manifestation of AS. 
The National Ankylosing Spondylitis Society of the UK reports that 
uveitis occurs in 30 - 40% of patients with AS.[31] The association of an 
increased risk of uveitis with etanercept compared with other TNFi is 
starting to become less controversial. In a recent article published in 
the Annals of Rheumatic Disease (2017),[29] a Swedish registry study 
reported a 2 - 4-fold increased risk of anterior uveitis associated with 
etanercept compared with infliximab or adalimumab within 2 years 
of initiating treatment in AS patients. Lim et al.,[30] in a registry-
based study, also showed a significant drug-specific relationship of 
uveitis associated with etanercept in comparison with infliximab 
and adalimumab after excluding patients with systemic diseases 
such as AS, JIA, PsA and Crohn’s disease associated with uveitis. In 
view of the above, our unit will preferentially be using infliximab or 
adalimumab instead of eternacept for AS patients with a history of 
uveitis.
A single patient on etanercept developed PTB, as mentioned 
above. He was not on continuous INH prophylaxis at the time of 
his PTB diagnosis, which may have contributed to his PTB disease 














Fig. 4. Response to first biological in rheumatoid arthritis patients (n=6). 
Median (IQR) CDAI score improved from 39 (34.5 - 43) to 21 (18.7 - 25.5) 
by the end of the study or discontinuation of the drug (statistically significant 
difference of –17.4 (p=0.044) (95% CI –34.1 - –0.7) over a median (IQR) 
time period of 39 (21 - 50) months). (IQR = interquartile range; CDAI = 















Fig. 5. Response to second biological in ankylosing spondylitis patients 
(n=4). Median (IQR) BASDAI score improved from 3.4 (2.7 - 5) to 2.2 
(1.4 - 3.3) by the end of the study (non-statistically significant difference of 
–1.23 (p<0.7) (95% CI –4.13 - 6.63) over a median (IQR) time period of 
9  (8 - 12) months). (IQR = interquartile range; BASDAI = Bath Ankylosing 
















Fig. 6. Response to second biological in rheumatoid arthritis patients 
(n=4). Median (IQR) CDAI score improved from 24.5 (20.3 - 28.5) to 4 
(3.5 - 5.0) by the end of the study (statistically significant difference of –20.3 
(p=0.001) (95% CI –8.0 - –32.5) over a median (IQR) time period of 13 (5  - 
28) months). (IQR = interquartile range; CDAI = Clinical Disease Activity 
Index; CI = confidence interval.)
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TB disease. Although the number of patients has been small, the 
chemoprophylaxis protocol implemented at TBH as previously stated 
seems to be effective in preventing TB.
A recent comparison between the South African Biologics Registry 
(SABIO) and reported data from international registries found 
a 10-fold higher incidence of TB among SA patients receiving 
biological therapy. The significantly higher incidence is probably due 
to the high TB prevalence in SA, with the added risk of biological 
therapy. Strong consideration should therefore be given to available 
alternatives such as rituximab or abatacept for patients with RA. 
For AS, only TNFi are currently available in the state sector, with 
ustekinumab (Stelara) being a safer alternative available in the private 
sector. Unpublished data from SABIO did not reveal a significant 
difference between etanercept and non-TNFi in terms of TB risk.[32]
Infusion reactions to rituximab, such as cough, dyspnoea and 
bronchospasm, are known complications of which the practitioner 
needs to be aware,[33,34] and bronchospasm occurred in one patient 
in our study.
We found a statistically significant decrease in disease activity 
scores of the various arthritides. The associated slowing of disease 
progression ultimately limits disability in the long term, which has 
a beneficial effect on employment status and future prospects.[35,36] 
The efficacy of the second biological therapies in the AS group was 
not as pronounced as that of the first biological therapies, which may 
be explained by the fact that a significant proportion of patients were 
switched to a second biological drug because of adverse events while 
already achieving an improvement in disease activity scores after the 
first biological therapy. A sustained response rather than treatment 
failure is therefore reflected in the figures. The other potential 
contributing factor might be the shorter time exposed to the second 
biological therapy (median (IQR) 9 (8 - 12) months) compared with 
the first (20 (9 - 30) months). It should be noted that this study was 
not powered to assess efficacy of biological therapies.
Gaining access to biological therapy for a selected group of 
patients in the state sector led to the setting out of a number of 
goals by the Division of Rheumatology at TBH. One of these was 
to reduce disability and limit the impact of the disease by regaining 
and retaining employment. The SA unemployment rate reached 
a 15-year high of 29% in 2019,[37] adding to the various factors 
influencing employment status in patients with a disabling disease 
such as RA or AS. Selecting patients who are motivated to continue 
working or regain employment by means of a thorough occupational 
therapy and social worker assessment seems to be effective. This 
effectiveness is evident by the fact that most patients were able 
to retain employment, two patients gained employment and two 
patients reached pensionable age.
Study limitations
This study was done retrospectively and relied on the accuracy of 
reports on adverse events and clinical data. The small number of 
patients included in the study is a reflection of the impact of severe 
resource constraints. It does, however, limit the statistical strength 
of some of the results reported. Selection bias with regard to specific 
conditions treated as well as the type of biological therapy used was 
explained earlier in the article.
Conclusions
We report on a selected group of patients who received biological 
therapy for various rheumatological conditions. The majority of 
patients showed a significant clinical response to treatment.
Recurrent uveitis occurred in almost half of the patients 
with ankylosing spondylitis and was also the main reason for 
discontinuation of biological therapy. We did not document an 
increased risk of PTB in our patients. The screening as well as 
the chemoprophylaxis protocol implemented at TBH appears 
to be effective in preventing reactivation of or infection with 
Mycobacterium tuberculosis; however, considering the small numbers 
and the fact that this was a single-centre study, conclusions are 
limited. To determine the true risk of TB associated with biological 
therapy and the efficacy of current TB prophylaxis in a high-risk 
community will require multi-centre registry verification, comparing 
the data with a csDMARD rheumatological control group.
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